Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has been assigned a consensus rating of “Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $10.57.

A number of analysts have recently weighed in on the stock. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research report on Friday. Lake Street Capital decreased their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Monday. Finally, Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday.

Institutional Investors Weigh In On Aquestive Therapeutics

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its position in Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after buying an additional 621,614 shares in the last quarter. State Street Corp increased its stake in shares of Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after acquiring an additional 512,682 shares during the last quarter. Stifel Financial Corp raised its holdings in shares of Aquestive Therapeutics by 315.4% during the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company’s stock worth $1,419,000 after acquiring an additional 302,617 shares in the last quarter. Harvey Capital Management Inc. boosted its position in Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after purchasing an additional 249,790 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new position in Aquestive Therapeutics in the third quarter valued at about $995,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Trading Down 4.2 %

Shares of AQST opened at $2.54 on Thursday. The stock’s fifty day simple moving average is $3.07 and its 200 day simple moving average is $4.09. Aquestive Therapeutics has a twelve month low of $2.24 and a twelve month high of $6.23. The firm has a market capitalization of $251.13 million, a P/E ratio of -5.64 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to the consensus estimate of $13.11 million. Sell-side analysts predict that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.